Viking’s stock has stabilized in recent sessions, trading in the mid-$30s after a roller-coaster few months. It ended Friday at $33.53marketbeat.com, roughly flat on the week and not far from its intraday high of ~$36.80 on Thursdayir.vikingtherapeutics.com. This marks a dramatic recovery from mid-August, when VKTX plunged over 40% in one day following a crucial trial announcementts2.tech. Back then, Viking had unveiled results from a Phase 2 study of its oral obesity pill that missed investor expectations, triggering a sharp selloff. Since that rout, the stock has climbed back as optimism returns ahead of key catalysts. Heavy trading activity underscores the renewed interest – on Oct. 15, nearly 22,823 call options on VKTX traded, including a burst of bullish bets at the $50 January strikets2.tech. This elevated options volume suggests traders positioning for potential upside moves.
